FindTrial
Sign In

A study to determine how BI 907828 (Brigimadlin) is taken up in the tumor (Phase 0) and to determine the highest dose of BI 907828 (Brigimadlin) that could be tolerated (Phase Ia) in combination with radiation therapy in people with a brain tumor called glioblastoma

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-506409-20-00
Acronym
1403-0007
Enrollment
14
Registered
2023-11-06
Start date
2023-11-24
Completion date
2025-07-31
Last updated
2025-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Interventions

None listed

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Belgium, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026